Tan Juntao, Zhu Daqing, Li Guobiao, Hu Hai, Lai Zongqiang, Li Zhihua
Jiangxi Province Key Laboratory of Breast Diseases, Nanchang People's Hospital, Nanchang, China.
Department of Infectious Disease, Fifth People's Hospital of Ganzhou, Ganzhou, China.
Nanomedicine. 2025 Aug;68:102834. doi: 10.1016/j.nano.2025.102834. Epub 2025 Jun 13.
Triple-negative breast cancer (TNBC) lacks effective targeted therapies due to absent hormone receptors and HER2 expression, often resulting in poor prognosis. This study developed a theranostic system, AptPD-L1-FSNPs, combining PD-L1 aptamers with fluorescent silica nanoparticles (FSNPs) for targeted imaging and therapy in TNBC.
PD-L1 aptamers were conjugated to FSNPs, forming AptPD-L1-FSNPs. In vitro binding was evaluated using PD-L1-positive TNBC cells and negative controls. In vivo tumor targeting and biodistribution were assessed via fluorescence imaging in TNBC-bearing mice. Therapeutic efficacy was measured by tumor growth inhibition, survival, and apoptosis, with toxicity assessed in major organs.
AptPD-L1-FSNPs showed high specificity to PD-L1-expressing TNBC cells and prolonged tumor retention in vivo. Treatment led to reduced tumor growth, increased apoptosis, and improved survival with minimal toxicity.
AptPD-L1-FSNPs offer targeted TNBC imaging and therapeutic potential, demonstrating promise for future clinical applications in personalized cancer treatment.
三阴性乳腺癌（TNBC）由于缺乏激素受体和HER2表达，缺乏有效的靶向治疗方法，常常导致预后不良。本研究开发了一种诊疗系统，即AptPD-L1-FSNPs，它将PD-L1适体与荧光二氧化硅纳米颗粒（FSNPs）相结合，用于TNBC的靶向成像和治疗。
将PD-L1适体与FSNPs偶联，形成AptPD-L1-FSNPs。使用PD-L1阳性的TNBC细胞和阴性对照评估体外结合情况。通过对荷瘤小鼠进行荧光成像评估体内肿瘤靶向性和生物分布。通过肿瘤生长抑制、生存率和细胞凋亡来测量治疗效果，并对主要器官的毒性进行评估。
AptPD-L1-FSNPs对表达PD-L1的TNBC细胞表现出高特异性，并在体内延长了肿瘤滞留时间。治疗导致肿瘤生长减缓、细胞凋亡增加且生存率提高，同时毒性最小。
AptPD-L1-FSNPs具有TNBC靶向成像和治疗潜力，为未来个性化癌症治疗的临床应用展示了前景。
